Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
Rajiv Agarwal(Richard L. Roudebush VA Medical Center), Stefan D. Anker(Bayer (Germany)), George L. Bakris(Pennsylvania State System of Higher Education), Gerasimos Filippatos(National and Kapodistrian University of Athens), Luís M. Ruilope(Bayer (Germany)), Bertram Pitt(Bayer (Germany)), Peter Kolkhof(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Martin Gebel(Bayer (Germany)), Peter Rossing(Steno Diabetes Centers), Christina Nowack(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Amer Joseph(Berlin Institute of Health at Charité - Universitätsmedizin Berlin)
Cited by 1,169
Related Papers
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|Hypertension|2003|13.3k
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k